{"name":"Pharma Two B Ltd.","slug":"pharma-two-b-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Marketed Pramipexole ER","genericName":"Marketed Pramipexole ER","slug":"marketed-pramipexole-er","indication":"Parkinson's disease (motor symptoms)","status":"phase_3"}]}],"pipeline":[{"name":"Marketed Pramipexole ER","genericName":"Marketed Pramipexole ER","slug":"marketed-pramipexole-er","phase":"phase_3","mechanism":"Pramipexole is a dopamine D2/D3 receptor agonist that stimulates dopamine signaling in the brain to improve motor control and reduce symptoms of Parkinson's disease.","indications":["Parkinson's disease (motor symptoms)","Restless legs syndrome"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNbUhwYThzWVNWV29DNzJScjZIQk5lMzRHbnZ0RjJ3eFFKdzMtb2t4UDMzRG9mRW41dGdic2tVVDhncUdMZzBubGg1LUhKdkJFelZ5QjZVeF9jLWY0Tk1jamVxTWpvRFVUaF9ZYWZfV2RrTjVQZV84c1l6TlRHTFBxeUV3VlludWs3T3JBLTlhbFFjbVh3cldYQ3Vpck5BLUN2T1R1bEFqYnJjRjVVOXk3WVRKVi13dWwzN0ptWE9OTjdMVWVjZ3pj?oc=5","date":"2026-03-06","type":"pipeline","source":"Stock Titan","summary":"Medicus Pharma (MDCX) registers 1.12M shares; Yorkville bought 4.47M shares - Stock Titan","headline":"Medicus Pharma (MDCX) registers 1.12M shares; Yorkville bought 4.47M shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOei1rdm9MWHZEOEtKRVRQNzhROG1zQjFDVXNmWTBfTHNZc1BOUzUwMUhKMFpxQ09xY2FHRnJkZ2pnMGZFWkNPVnFzQVpYVG5Vc3cwZEU1QU5FMTdyeC1kQXk3LTJXeldxVzdVV282QVdiRDlEaXVKcmNWRzVqU3NjMVFsNUxmdldGNnBQZ2ZxNXZjeE01a0NRbWlOSk9tMXBvZzVacC14LXo?oc=5","date":"2026-03-03","type":"pipeline","source":"AFR","summary":"BGH Capital woos co-investors for $2.4b pharmaceutical bet - AFR","headline":"BGH Capital woos co-investors for $2.4b pharmaceutical bet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_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?oc=5","date":"2026-02-06","type":"pipeline","source":"simplywall.st","summary":"Kubota Pharmaceutical Holdings Co., Ltd.'s (TSE:4596) market cap up JP¥5.9b last week, benefiting both individual investors who own 46% as well as insiders - simplywall.st","headline":"Kubota Pharmaceutical Holdings Co., Ltd.'s (TSE:4596) market cap up JP¥5.9b last week, benefiting both individual invest","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxPZG1pZlNEOUpKZVo1UC1seGhDWWNqMnpfSHloZlJYSW03VE1XZTcwb2xIVGgtNXI5dnFkUUdnSDJXdVlMTU4zYkUxMjh3ZDk0OE95c184cXFGNEgzUlN5R21ldlFTM1YyX3ZoNk5TS1hnWlNibE1zTmpmdzFULTRQTVZINEZ1aDh5RGxsS0hLQlVsall3LXZkYU0xdERaU3pZYWk1SlU1ZGU4Q2F6STd6aDBLQS1XUkpMZWVlVEQwOGwyakhteFdrTDZ3S3h2WFZIVnY2a3B4X0JtOENlX21TWmxmLWtkX1V6VGp2cERzN29NMkxZdjQ0U2p0cXhyNkJrTnJrRG10ems4VzVITnpzY2V2SGMtRXNobk9KQXc1R29Hc181SlJTN21wOVZkWEVXaFJaOWd1WVQ2VkJuQUZrdkZOdjhCdDg?oc=5","date":"2025-08-20","type":"regulatory","source":"Barchart.com","summary":"Parkinson’s Disease Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail - Barc","headline":"Parkinson’s Disease Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi_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?oc=5","date":"2025-08-06","type":"trial","source":"businesswire.com","summary":"Retension Pharmaceuticals Announces Completion of Series B Financing to Advance Phase 2b Trial for Uncontrolled and Resistant Hypertension and Issuance of a New U.S. Patent Covering its Lead Candidate","headline":"Retension Pharmaceuticals Announces Completion of Series B Financing to Advance Phase 2b Trial for Uncontrolled and Resi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQcjJMRUFYZWltLW44Vm1ueUlmNzNGclBkNjZ5TktpQ3NLTHlsX0J6OVA3eFM5aDNxN0RVcnJTb05sZi1kTjVnLVpPaVZySnl4b1B0S1VTaUdkUEVHMncyZmdLLXkyWF9qTy1RS1k2VzhmclBJLW1vSjZxUkpueVJJRml5M3FsbzNhRmpVaGc3eHJOQQ?oc=5","date":"2025-07-16","type":"regulatory","source":"Seeking Alpha","summary":"Nasus Pharma IPO Shows Promise But Risks Remain (NSRX) - Seeking Alpha","headline":"Nasus Pharma IPO Shows Promise But Risks Remain (NSRX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPdkduZS15bGxsVDQ2Tkc4TzZLU0hXNHYxbE9DLUZGTEw3MVE1SXdjcWQyUm45MnV3UzloVnc5cWRBSk1MeHA5OW5kb25pdmZFQ3ZLRGdBd0hqNHRkQWdHbEtSZjVEZjdCMlp3cUR4Vm9VeVY2aFRzQ0hZNnFIUkNnV1ZEazJ3MnJuSXM1ZFBYbGhpdU5vVl92MHFNaUFKM3M2UXc?oc=5","date":"2025-07-01","type":"deal","source":"BioWorld News","summary":"Torrent Pharma to buy JB Pharma from KKR in $3B M&A deal - BioWorld News","headline":"Torrent Pharma to buy JB Pharma from KKR in $3B M&A deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNajF0VlgtS043TFZidXozcUlYT3VjNXBFTmhCSGxJdUE0RVdzSnBWaGVWdDUtSHlSckk3VmtnUXJ4UFFNMk9BMUFzaU92WkpHXy1Uc2RHZzFPNFlKOGpfYlB5NzBOS2JxN3dQZGZucmV4YjRzclYtV3FEUWI0OWZGYnM4cUxXM1U0Z3FOLTJaNGJZWlVvVjlLUDQyUWRwRnJqNmZjU0lLUDlWbk5MU3JtRmFVejdKbmxmTXhFLWVVZ2xFWVU?oc=5","date":"2025-06-30","type":"deal","source":"BioSpace","summary":"Torrent Pharma to Acquire Controlling Stake in J. B. Chemicals & Pharmaceuticals from KKR - BioSpace","headline":"Torrent Pharma to Acquire Controlling Stake in J. B. Chemicals & Pharmaceuticals from KKR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQSktKUVIzR0E0c3A4MGFXWFBBSlczMm8tcUwwaWFLaHJBODd5QVJHdGF6QUM1TzVLWENjRFVUcVRnQUh6X0xsYlN2d1hTSUI3U0NiMHNJZGNOTklCRzc4cmcxOXZxZHo5WG5pZDJUWHc1dFlzZUZySGdCV1hqLUU5UE9aQW1CSUI1aldtMWItWXIzREdsWm1kVFo2YThyY3ZMY0ZpbHl0ZEFjLUpJT2pVbw?oc=5","date":"2024-12-11","type":"deal","source":"Fierce Biotech","summary":"Reverse, reverse: Liver disease biotech Hepion and Pharma Two B call off merger - Fierce Biotech","headline":"Reverse, reverse: Liver disease biotech Hepion and Pharma Two B call off merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPWXVPT3k4MktzYzFOZGpubVU0Y1VRZmRFczkyeDdpeHAwVXNaUWE1cm4xang0NDdrRndEUFJaTHNyb1Bvamo2YlpQWmJnc3VXbUFhWEk2LXFhUkt1VVJMN1FkNnBaYUkzVjFHelNyUmYtYVY4NFA3TlFuREp3TFZidg?oc=5","date":"2024-12-05","type":"trial","source":"Yahoo Finance","summary":"Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group - Yahoo Finance","headline":"Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPTk5SSXE1Y0YyZFFSRnNocjVVOHhLQWdCd2FISl8tVWd4c0hsMGJQX3pLb0FDOTJjd0FreHQyMzBBaUNCLXFQTUJpVG1BNEE5M2plVzA1Y3hZRmgwUE1od0xwcUV6NXZkUWhmOXFkaGFPU0NOZmkxam5QYThfREtKc09kbGJ6eVA0?oc=5","date":"2024-11-11","type":"deal","source":"Yahoo Finance","summary":"Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger - Yahoo Finance","headline":"Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNT0RaNEEyWnRxYnNhZ3RPUVFwYXJXa3lDd1EzdnBZb2JVZkxaR0ZrdTRlb0djZVVOeTItdmdlbFVxMmFTaWdtUmhGWTJoWkZONnJrUVZhNXhvTFZNamZfcmxZcThmNFpGb29lOWltckpTYXdUN3Zsc1RJdjBHNy1XTjFKZzBvWVdmNTY5YUxWMXlpcHQ0YjcwaU56cHRDSkd3bDlta3ltZjhCUQ?oc=5","date":"2017-02-27","type":"pipeline","source":"PR Newswire","summary":"Pharma Two B Ltd. Closes $30 Million Financing Round - PR Newswire","headline":"Pharma Two B Ltd. Closes $30 Million Financing Round","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}